Julija Čiauškaitė

Ms. Julija Čiauškaitė

Department of Neurology, Medical Academy, Lithuanian University of Health Sciences
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in Medicina
Verified
Journal Article
Open access
PDF file
Julija ČiauškaitėJulija Čiauškaitė
Julija Čiauškaitė
GGGiedrė Gelžinienė
Giedrė Gelžinienė
GJGiedrė Jurkevičienė
Giedrė Jurkevičienė
Background and Objectives: Hyponatremia is one of the most common adverse effects in patients treated with oxcarbazepine (OXC). Different risk factors for OXC-induced hyponatremia have been described as age, female gender, dosage, and combination with other drugs During our clinical practice, we noticed that a longer duration of treatment with OXC could be associated with a higher risk of hyponatremia, therefore, in this study, we aimed to evaluate factors that may increase the risk of OXC-induced hyponatremia. Materials and Methods: Data were retrospectively collected from our clinical database at the Department of Neurology of the Hospital of Lithuanian University of Health Sciences Kaunas Clinics. The sample was divided into three groups: OXC consumers (n = 31), other anti-seizure medications (ASMs) consumers (n = 43), and controls absent ASMs (n = 31). All groups were matched by age and gender. Hyponatremia was defined as <136 mmol/L. Results: The frequency of hyponatremia was significantly higher among OXC patients (61.3%) compared to other ASM patients (5.4%) and controls (3.2%). The mean serum sodium concentration in the OXC group was 133.1 ± 5.1 mmol/L. The frequency of severe hyponatremia among OXC-treated patients was 19.4%; this subgroup was older than patients with moderate hyponatremia and normonatremia and had a longer OXC treatment duration compared to a subgroup of normonatremia. The average duration of OXC therapy was 8.7 ± 5.5 years with a range from 1 to 21 years. Serum sodium concentration and duration of treatment with OXC demonstrated a significant negative correlation (r = −0,427, p = 0.017). Each year of therapy with OXC increased the risk of hyponatremia 1.3 times (OR = 1.326, 95% Cl 1.027–1.712, p = 0.031). Other factors (gender, age, polypharmacy, OXC dosage, and serum concentration) did not show a significant association with the development of hyponatremia. Conclusions: Longer duration of treatment with OXC is an important factor in the development and severity of hyponatremia.

1 April 2024 in Medicina
Verified
Journal Article
Open access
PDF file
MNMatas Nasvytis
Matas Nasvytis
Julija ČiauškaitėJulija Čiauškaitė
Julija Čiauškaitė
GJGiedrė Jurkevičienė
Giedrė Jurkevičienė
GNB1 encephalopathy is a rare genetic disease caused by pathogenic variants in the G Protein Subunit Beta 1 (GNB1) gene, with only around 68 cases documented worldwide. Although most cases had been caused by de novo germline mutations, in this case, the pathogenic variant was inherited from patient’s mother, indicating an autosomal dominant inheritance pattern. The patient presented at 25 years of age with mild developmental delay and cognitive impairment, prominent generalized dystonia, and horizontal nystagmus which are all characterizing symptoms of GNB1 encephalopathy. Electroencephalography (EEG) showed no epileptiform patterns, and magnetic resonance imaging (MRI) revealed hypointensities in globus pallidus and dentate nucleus areas. The main theory for GNB1 encephalopathy pathogenesis is neuronal hyperexcitability caused by impaired ion channel regulation. Due to low specificity of symptoms, diagnosis relies on genetic testing. As there are no standardized GNB1 encephalopathy treatment guidelines, evaluation of different treatment options is based on anecdotal cases. Reviewing different treatment options, deep brain stimulation and intrathecal baclofen pump, as well as some other medications still in preclinical trials, seem to be the most promising.

24 August 2021 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
Julija ČiauškaitėJulija Čiauškaitė
Julija Čiauškaitė
IPIeva Puleikytė
Ieva Puleikytė
SJSimonas Jesmanas
Simonas Jesmanas
GJGiedrė Jurkevičienė
Giedrė Jurkevičienė
AVAntanas Vaitkus
Antanas Vaitkus
DRDaiva Rastenytė
Daiva Rastenytė
Creutzfeldt‐Jakob disease (CJD) is a rare rapidly progressive fatal neurodegenerative disease. Neuroleptic malignant syndrome (NMS) is a complication of antipsychotic medications which may be used to treat neuropsychiatric symptoms of CJD. We present a case of a 51‐year‐ old woman with CJD who developed NMS after being prescribed quetiapine.

23 June 2021
Verified
Preprint
Open access
PDF file
Julija ČiauškaitėJulija Čiauškaitė
Julija Čiauškaitė
IPIeva Puleikytė
Ieva Puleikytė
SJSimonas Jesmanas
Simonas Jesmanas
GJGiedrė Jurkevičienė
Giedrė Jurkevičienė
AVAntanas Vaitkus
Antanas Vaitkus
DRDaiva Rastenytė
Daiva Rastenytė
Creutzfeldt – Jakob disease (CJD) is a rare neurodegenerative disease with complex clinical manifestations. Neuroleptic malignant syndrome (NMS) is a complication of antipsychotic medications which are used to treat neuropsychiatric symptoms of CJD. We present a case of a 51-year-old woman with CJD who developed NMS after being prescribed quetiapine.